Dr. Vivek's AI Dr. Vivek's AI
Support us
🔗 You are viewing a shared knowledge page for: Pediatric Cld
← New Search

Pediatric Cld

Educational clinical summary of Pediatric Cld for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Overview

  • Definition: Chronic Lung Disease (CLD), commonly referred to as Bronchopulmonary Dysplasia (BPD) in neonates, is a chronic respiratory condition primarily affecting preterm infants. It is characterized by persistent oxygen requirement beyond 28 days of postnatal age, with radiographic and clinical evidence of lung disease. The definition has evolved, and the contemporary definition often links the severity to oxygen requirement and supportive care at 36 weeks postmenstrual age (PMA).
    • NIH Consensus Definition (2001):
      • Mild BPD: Oxygen requirement ≥ 28 days but resolution by 36 weeks PMA (or discharge, whichever comes first).
      • Moderate BPD: Oxygen requirement ≥ 28 days and still requiring supplemental oxygen at 36 weeks PMA, but at FiO2 < 0.30.
      • Severe BPD: Oxygen requirement ≥ 28 days and still requiring supplemental oxygen at 36 weeks PMA, and/or positive pressure ventilation (NIPPV, CPAP, mechanical ventilation), or FiO2 ≥ 0.30.
  • Epidemiology:
    • Incidence varies by gestational age and birth weight, inversely proportional to both.
    • Affects approximately 10,000 to 15,000 infants annually in the US.
    • Incidence in infants born <28 weeks gestation can be as high as 60-70%.
    • Incidence in infants <1500g (VLBW) is about 20-30%.
    • Higher rates in males than females.
    • Significant leading cause of morbidity and mortality in survivors of extreme prematurity.
  • Classification:
    • Historically, "old BPD" was characterized by severe airway inflammation and fibrosis, often secondary to high ventilator pressures and oxygen toxicity.
    • "New BPD" (or contemporary BPD) is more common in extremely preterm infants and is characterized by less severe inflammation and fibrosis, but impaired alveolar and vascular development leading to fewer and larger alveoli and dysmorphic pulmonary vasculature. This distinction is important for understanding pathophysiology and treatment strategies.

Pathophysiology

  • Mechanism: BPD is a multifactorial disease that arises from the arrest of lung development, particularly alveolarization and angiogenesis, in susceptible preterm infants. This developmental arrest is exacerbated by postnatal insults.
    1. Impaired Lung Development: Extremely premature infants are born during the saccular and alveolar stages of lung development. Insults during this critical period prevent normal septation and angiogenesis.
    2. Inflammation: Perinatal infection (chorioamnionitis, sepsis), ventilator-induced lung injury, and oxygen toxicity trigger a cascade of inflammatory mediators (cytokines, chemokines, proteases) that can damage lung parenchyma and impair repair.
    3. Ventilator-induced Lung Injury (VILI): Barotrauma (high pressures), volutrauma (overdistention), atelectotrauma (repeated alveolar collapse and reopening), and biotrauma (inflammation from mechanical stretch) contribute significantly.
    4. Oxygen Toxicity: High concentrations of oxygen generate reactive oxygen species (ROS) that injure lung cells (epithelial, endothelial), inhibit growth factors, and provoke inflammation.
    5. Genetic Predisposition: Polymorphisms in genes related to inflammation, oxidative stress, and lung development may increase susceptibility.
    6. Nutritional Deficiencies: Inadequate nutrition can hinder lung repair and growth.
    7. Pulmonary Vascular Dysregulation: Abnormal development or remodeling of pulmonary vessels contributes to pulmonary hypertension, a common complication.
  • Risk Factors:
    • Extreme Prematurity (<28 weeks gestation): Most significant risk factor.
    • Very Low Birth Weight (<1000g): Strong association.
    • Mechanical Ventilation: Prolonged duration, high pressures/volumes.
    • High Supplemental Oxygen Exposure: Especially early in life.
    • Perinatal Infection/Inflammation: Chorioamnionitis, sepsis, necrotizing enterocolitis (NEC).
    • Patent Ductus Arteriosus (PDA): Especially if hemodynamically significant, leading to pulmonary edema.
    • Sepsis (postnatal).
    • Genetic polymorphisms.
    • Male sex.
    • Maternal factors: Chorioamnionitis, maternal smoking, preeclampsia.
    • Pulmonary Hypertension.
  • Protective Factors:
    • Antenatal Corticosteroids: Reduces incidence and severity of RDS.
    • Gentle Ventilation Strategies: Permissive hypercapnia, early extubation, non-invasive ventilation (NIPPV, CPAP).
    • Minimizing Oxygen Exposure: Targeting appropriate oxygen saturation ranges (e.g., 90-95%).
    • Caffeine Citrate: Reduces duration of ventilation and BPD incidence.
    • Early and Aggressive Nutrition: Parenteral and enteral.
    • Early PDA closure (in select cases).
    • Surfactant Therapy: Reduces severity of RDS, indirectly reducing BPD.

Clinical Presentation

Signs and Symptoms

  • Cardinal Features:
    • Persistent tachypnea (respiratory rate >60 breaths/min in infants).
    • Retractions (subcostal, intercostal, subxiphoid).
    • Nasal flaring.
    • Prolonged oxygen requirement (beyond 28 days and often at 36 weeks PMA).
    • Failure to thrive.
  • Early Signs:
    • Difficult weaning from mechanical ventilation or CPAP.
    • Persistent hypoxemia despite supplemental oxygen.
    • Increased work of breathing after initial recovery from RDS.
    • Frequent desaturations, especially during feeds or sleep.
  • Advanced Signs:
    • Persistent crackles, wheezes on auscultation.
    • Digital clubbing (in severe, long-standing cases).
    • Signs of right heart failure (cor pulmonale) secondary to severe pulmonary hypertension: hepatomegaly, peripheral edema, distended neck veins (rare in infants, but possible with severe PH).
    • Recurrent hospitalizations for respiratory infections (RSV, influenza, Rhinovirus).
  • Atypical Presentations:
    • Silent hypoxemia without overt signs of distress, especially in well-compensated infants.
    • Delayed onset of severe symptoms, sometimes seen after discharge due to viral infections.
    • Significant growth failure without obvious respiratory distress, where increased metabolic demands of breathing contribute.

Physical Examination

  • Inspection:
    • General: Thin, sometimes pale, poor weight gain, small for age.
    • Respiratory: Tachypnea, nasal flaring, subcostal/intercostal/subxiphoid retractions, suprasternal indrawing. Accessory muscle use.
    • Chest Shape: Increased anteroposterior diameter (barrel chest) in severe cases due to air trapping. Pectus excavatum or carinatum can occur.
    • Oxygen Support: Presence of NC oxygen, ventilator, tracheostomy.
    • Cardiac: Visible precordial impulse, signs of increased right ventricular activity.
  • Palpation:
    • Chest: Diminished tactile fremitus if air trapping, but often nonspecific.
    • Abdomen: Hepatomegaly suggestive of right heart failure.
  • Special Tests:
    • Auscultation: Diffuse crackles (rales), crepitations (reflecting fluid or fibrosis), wheezes (bronchoconstriction or airway malacia), rhonchi. Areas of decreased breath sounds.
    • Pulse Oximetry: Continuous monitoring to assess oxygen saturation (SpO2) and identify desaturations. Target SpO2 generally 90-95% for most stable BPD infants.
    • Blood Pressure: May be normal or show signs of systemic hypertension (more common if severe chronic disease contributing to renal issues, or related to steroid use).

Diagnostic Approach

History Taking

  • Key Questions:
    • Perinatal history: Gestational age, birth weight, antenatal steroid use, maternal infections, APGAR scores, need for resuscitation.
    • Neonatal course: Duration of mechanical ventilation, highest FiO2/pressure, surfactant use, oxygen duration, caffeine, PDA treatment, sepsis episodes, fluid intake/output.
    • Respiratory history: Current oxygen requirement (flow rate, FiO2), frequency/severity of desaturations, current respiratory support (CPAP, NIPPV, tracheostomy), history of intubation/re-intubation, nebulizer use, medication history (diuretics, bronchodilators, steroids). Respiratory symptoms: cough, tachypnea, wheezing.
    • Feeding history: Oral intake, gavage/NGT/OGT/PEG tube dependence, caloric density of feeds, weight gain pattern.
    • Growth and Development: Weight, length, head circumference trajectory. Developmental milestones.
    • Hospitalizations: Number and causes of readmissions after discharge (e.g., respiratory syncytial virus, pneumonia).
    • Family history: Asthma, atopy, other chronic lung diseases.
  • Red Flags:
    • Acute increase in oxygen requirement or work of breathing.
    • Persistent or worsening desaturations despite increased oxygen.
    • Apnea.
    • Signs of respiratory distress (severe retractions, grunting, gasping).
    • Cyanosis.
    • Poor feeding, lethargy, decreased activity.
    • Signs of right heart failure (e.g., new onset hepatomegaly, peripheral edema).
    • Sudden onset of hemoptysis or stridor.

Laboratory Tests

  • First-Line:
    • Arterial Blood Gas (ABG) or Capillary Blood Gas (CBG): Assess pH, pCO2, pO2, bicarbonate to evaluate respiratory status, detect hypercapnia or hypoxemia, and assess acid-base balance.
    • Complete Blood Count (CBC): Rule out anemia (can exacerbate respiratory distress), identify signs of infection (leukocytosis, neutropenia).
    • Electrolytes: Monitor for electrolyte imbalances, especially with diuretic use (hyponatremia, hypochloremia, hypokalemia).
    • Blood cultures: If infection suspected.
    • Brain Natriuretic Peptide (BNP/NT-proBNP): Can be elevated in pulmonary hypertension or cardiac dysfunction; not routinely diagnostic but can aid in risk stratification and monitoring.
  • Confirmatory: No single laboratory test confirms BPD; it's a clinical and radiological diagnosis. Lab tests support diagnosis and rule out other conditions.
  • Monitoring:
    • Electrolytes: Regularly, especially with chronic diuretic therapy.
    • Growth parameters: Serial weight, length, head circumference.
    • Renal function (BUN/SCr): If on nephrotoxic medications or diuretics.
    • Liver function tests: If concerns about liver involvement or long-term parenteral nutrition.

Imaging

  • Recommended:
    • Chest Radiograph (CXR):
      • Early in course: Often shows diffuse granular pattern (RDS).
      • By 2-4 weeks: May show hazy infiltrates, poorly defined cardiac borders, hyperinflation, and patchy atelectasis.
      • Classic "old BPD": Hyperinflation, cystic changes (lucencies), alternating areas of infiltrate and hyperlucency, streaky infiltrates, cardiomegaly.
      • "New BPD": Less severe cystic changes, often show subtle non-specific hyperinflation, diffuse hazy infiltrates, and sometimes decreased vascular markings. May appear surprisingly clear for severity of disease.
    • Echocardiogram with Doppler: Essential to screen for and assess extent of pulmonary hypertension (PH), quantify right ventricular function, identify structural cardiac anomalies (e.g., PDA, PFO, ASD), and assess for left heart dysfunction. Recommended at 36 weeks PMA in infants with moderate/severe BPD, and before discharge if they have moderate-to-severe BPD, or sooner if clinical signs suggest PH.
  • Advanced:
    • High-Resolution Computed Tomography (HRCT) of the Chest:
      • Not routinely recommended for initial diagnosis due to radiation exposure.
      • Indicated for persistent, unexplained respiratory symptoms, severe disease not responding to therapy, or to identify specific structural abnormalities (e.g., tracheomalacia, bronchomalacia, airway stenosis, congenital lung anomalies, interstitial lung disease, diffuse alveolar damage, mosaic perfusion pattern, air trapping) not visible on CXR.
      • Performed after 36 weeks PMA or when clinically stable enough.
    • Pulmonary Function Testing (PFTs):
      • Can be challenging in infants. Specialized techniques can measure lung volumes, compliance, and resistance.
      • Used in research or for specific clinical questions (e.g., evaluating response to bronchodilators, assessing severity of airway obstruction). Not routine for diagnosis.
    • Bronchoscopy:
      • Rarely needed for routine diagnosis of BPD.
      • Indicated for suspected airway obstruction (e.g., severe tracheo/bronchomalacia), recurrent lobar collapse, persistent atelectasis, suspected foreign body aspiration, or to obtain cultures/biopsies in specific cases of atypical lung disease.

Management

Acute Management

  • Immediate:
    • ABCDs: Ensure patent airway, adequate breathing, and circulation.
    • Oxygenation: Administer supplemental oxygen to maintain SpO2 targets (typically 90-95%, avoid hyperoxia).
    • Ventilatory Support: Optimize mechanical ventilation or non-invasive support as needed. Consider gentle ventilation strategies, short inspiratory times, low tidal volumes, and appropriate PEEP.
    • Fluid Balance: Strict fluid restriction if clinical evidence of pulmonary edema or fluid overload, but ensure adequate hydration for secretions.
    • Cardiovascular Support: Address signs of shock, treat arrhythmias.
  • Stabilization:
    • Respiratory Support:
      • Ventilation: If intubated, consider modes that minimize lung injury (e.g., volume-targeted ventilation).
      • Non-invasive strategies: Nasal CPAP, high-flow nasal cannula (HFNC) to support breathing and reduce work of breathing; can help with airway splinting.
    • Diuretics: May be used for pulmonary edema or fluid overload (e.g., Furosemide 1-2 mg/kg/dose IV/PO q12-24h; monitor electrolytes).
    • Bronchodilators: Inhaled beta-2 agonists (e.g., albuterol) and/or anticholinergics (e.g., ipratropium) for reversible bronchospasm. Trial and error to assess efficacy.
    • Steroids: Systemic corticosteroids (e.g., Dexamethasone 0.05-0.1 mg/kg/day divided BID for 3-5 days then taper) may be considered for severe exacerbations or difficult weaning, but judicious use due to significant side effects (neurodevelopmental, growth). Inhaled corticosteroids have not shown consistent benefit in acute exacerbations.
    • Antibiotics: Treat suspected or confirmed infections aggressively.
  • Emergency:
    • Acute Respiratory Failure: Intubation and mechanical ventilation.
    • Pneumothorax: Chest tube insertion.
    • Pulmonary Hemorrhage: Airway management, ventilation, blood product transfusion.
    • Severe Pulmonary Hypertension Crisis: Inhaled nitric oxide, IV prostacyclins, sildenafil.

Chronic Management

  • Pharmacological:
    • Oxygen Therapy: Maintain SpO2 90-95% for growth, neurodevelopmental outcome, and to prevent/treat pulmonary hypertension. Wean slowly as tolerated based on clinical stability and saturation monitoring. Home oxygen saturation study for discharge planning.
    • Diuretics: (e.g., Furosemide, Chlorothiazide, Spironolactone) for chronic fluid management, reduction of pulmonary edema, and improved lung mechanics. Monitor electrolytes weekly-biweekly.
      • Furosemide: 1-2 mg/kg/dose PO q12-24h
      • Chlorothiazide: 10-20 mg/kg/dose PO q12h
      • Spironolactone: 1-3 mg/kg/dose PO q12-24h
    • Bronchodilators: (e.g., Albuterol, Ipratropium bromide) for documented reversible airway obstruction or symptoms of bronchospasm. Use on PRN or scheduled basis after trial.
    • Inhaled Corticosteroids (ICS): Mixed evidence. May be considered in older infants/children with recurrent wheezing or significant airway hyperreactivity resembling asthma. Not typically first-line for primary BPD management in neonates.
    • Caffeine Citrate: For apnea of prematurity, and shown to reduce BPD. If still on caffeine, continue until apnea-free.
    • Sildenafil/Bosentan/Prostacyclin analogues: For pulmonary hypertension (PH). Initiated and managed by a pulmonologist/cardiologist.
    • Palivizumab (Synagis): Monthly IM injection (15 mg/kg) during RSV season for prevention of severe RSV disease in eligible BPD infants. Eligibility criteria are strict (e.g., <24 months old, requiring oxygen or medical support within 6 months of RSV season).
  • Non-pharmacological:
    • Nutritional Support: Crucial for lung repair and catch-up growth.
      • High-caloric formula (e.g., 24-30 kcal/oz) or breast milk fortified with human milk fortifier.
      • Close monitoring of growth parameters (weight, length, head circumference).
      • May require enteral feeding tubes (NG, G-tube) for adequate caloric intake.
      • Multivitamin and iron supplementation.
    • Fluid Management: Careful balance to prevent fluid overload while ensuring adequate hydration. Often 130-150 ml/kg/day, potentially less if pulmonary edema.
    • Respiratory Physiotherapy: Chest physical therapy (CPT), percussion, postural drainage for secretion clearance, as needed.
    • Developmental Support: Physical, occupational, and speech therapy referrals due to high risk of neurodevelopmental impairment.
    • Smoke-Free Environment: Avoid all tobacco smoke and other airway irritants.
    • Immunizations:
      • All routine childhood immunizations (DTaP, Hib, PCV13, IPV, Rotavirus, MMR, Varicella, Hepatitis B).
      • Annual influenza vaccine for infant and all household contacts.
  • Monitoring:
    • Regular Clinic Visits: Frequent follow-up with neonatology, pulmonology, cardiology, and developmental specialists.
    • Growth Monitoring: Strict monitoring of weight, length, head circumference.
    • Oxygen Saturation monitoring: Home pulse oximetry, overnight SpO2 studies to guide oxygen weaning.
    • Electrolytes: Regularly if on diuretics.
    • Echocardiograms: Serial echoes to monitor pulmonary hypertension and right ventricular function, typically every 3-6 months if PH present or clinically indicated.
    • Developmental Assessments: Formal developmental screening and assessment (e.g., Bayley Scales of Infant Development) to identify delays early.
    • Auditory and Visual Screening: Increased risk of hearing and visual impairments.

Treatment Algorithms

  • First-Line:
    1. Antenatal corticosteroids (for at-risk mothers).
    2. Surfactant therapy for RDS.
    3. Gentle ventilation strategies (volume-targeted, short inspiratory time, permissive hypercapnia, early extubation).
    4. Minimizing oxygen exposure (target SpO2 90-95%).
    5. Caffeine citrate.
    6. Optimal nutrition.
    7. Fluid restriction as needed.
    8. Diuretics for fluid retention/pulmonary edema.
    9. Supplemental oxygen for persistent hypoxemia.
  • Second-Line:
    1. Bronchodilators if reversible airway obstruction is present.
    2. Treatment of Patent Ductus Arteriosus (PDA) if hemodynamically significant.
    3. Pulmonary Hypertension (PH) specific therapy (sildenafil, bosentan) if PH persists despite oxygen.
    4. Systemic corticosteroids (e.g., short course dexamethasone) for severe, refractory cases of BPD where extubation is difficult, with careful consideration of risks.
  • Refractory Cases:
    • Tracheostomy and Home Ventilation: For infants with severe, long-standing BPD who cannot be weaned from mechanical ventilation.
    • Gastrostomy Tube (G-tube): For severe feeding difficulties and failure to thrive.
    • Lung Transplantation: Extremely rare, considered in select severe cases in older children with end-stage lung disease when all other options are exhausted. Requires specialized centers.

Complications

  • Common:
    • Respiratory infections: Increased susceptibility to RSV, influenza, rhinovirus, leading to frequent hospitalizations.
    • Pulmonary Hypertension (PH): Occurs in 20-40% of BPD infants, especially severe BPD, and is a significant predictor of mortality.
    • Airway obstruction/Malacia: Tracheomalacia, bronchomalacia, causing stridor, wheezing, and recurrent atelectasis.
    • Growth Failure/Failure to Thrive: Due to increased metabolic demands of breathing, poor feeding, and chronic illness.
    • Neurodevelopmental Impairment: Higher incidence of cerebral palsy, cognitive delay, speech delay, visual and hearing impairments compared to preterm infants without BPD.
    • Gastroesophageal Reflux Disease (GERD): Common, can exacerbate respiratory symptoms.
    • Subglottic Stenosis: From prolonged intubation.
  • Serious:
    • Acute Respiratory Failure: Requires re-intubation and intensive care.
    • Cor Pulmonale: Right ventricular failure due to severe, untreated pulmonary hypertension.
    • Severe Pulmonary Hypertension Crisis.
    • Pneumothorax/Pulmonary Air Leaks: Due to ventilator injury or fragility of the lung.
    • Aspiration Pneumonia: Due to GERD or swallowing dysfunction.
    • Cardiac Arrhythmias: Can occur secondary to hypoxemia, medications, or PH.
  • Long-term:
    • Persistent abnormal lung function: Restricted lung volumes, airway obstruction, exercise intolerance extending into childhood and adulthood.
    • Increased asthma risk.
    • Bronchiectasis: In severe cases.
    • Recurrent hospitalizations.
    • Chronic oxygen dependence.
    • Neurocognitive deficits and behavioral problems.

Prognosis

  • Factors:
    • Severity of BPD: Mild BPD has a better prognosis than moderate or severe BPD.
    • Presence and severity of pulmonary hypertension: PH is a major predictor of poor outcome and increased mortality.
    • Gestational age and birth weight: More premature and smaller infants generally have worse outcomes.
    • Comorbidities: Severe GERD, chronic aspiration, severe neurodevelopmental impairment.
    • Access to specialized care and ongoing support.
  • Survival:
    • Overall survival has improved with advances in neonatal care.
    • Infants with severe BPD, particularly those requiring tracheostomy and prolonged ventilation, have higher mortality rates, often driven by complications such as respiratory infections and pulmonary hypertension.
    • Mortality is highest in the first year of life.
  • Quality of Life:
    • Many children with BPD experience long-term respiratory symptoms (cough, wheeze, exercise intolerance) and require ongoing medical care.
    • Increased risk of school absences and healthcare utilization.
    • Neurodevelopmental outcomes vary widely; a significant proportion will have some developmental delays or learning difficulties.
    • Despite challenges, many individuals with milder forms can lead productive lives.

Prevention

  • Primary: Aimed at preventing the occurrence of BPD.
    • Prevention of preterm birth: Optimal obstetric care.
    • Antenatal Corticosteroids: Administered to mothers at risk of preterm delivery (e.g., Betamethasone 12mg IM q24h x 2 doses).
    • Optimized Delivery Room Care: Gentle resuscitation and early CPAP for spontaneously breathing preterm infants.
    • Surfactant Administration: Prophylactic or early rescue surfactant for RDS (e.g., Curosurf 2.5 mL/kg, Beractant 4 mL/kg).
    • Gentle Ventilation Strategies:
      • Volume-targeted ventilation.
      • Permissive hypercapnia (target pH 7.25-7.35, pCO2 50-65 mmHg), avoiding high pressures.
      • Minimizing invasive ventilation duration: Early extubation to non-invasive support (NIPPV, CPAP, HFNC).
      • Targeted SpO2 ranges: 90-95% to avoid both hypoxia and hyperoxia.
    • Caffeine Citrate: Reduces BPD and improves neurodevelopmental outcome (loading dose 20 mg/kg, then maintenance 5-10 mg/kg/day).
    • Nutritional Support: Early and adequate nutrition (optimized parenteral and enteral feeds).
    • Management of PDA: Judicious use of indomethacin/ibuprofen or surgical ligation for hemodynamically significant PDA.
  • Secondary: Early detection and intervention to mitigate severity.
    • Close monitoring of respiratory status, oxygen saturation, and growth in all premature infants.
    • Early identification and treatment of pulmonary hypertension.
    • Aggressive management of infections.
    • Appropriate fluid management.
  • Tertiary: Preventing complications and improving long-term outcomes.
    • Home oxygen therapy: For hypoxemic infants.
    • Palivizumab: To prevent severe RSV infection.
    • Comprehensive multidisciplinary follow-up: Pulmonology, cardiology, neonatology, developmental specialists.
    • Aggressive nutritional support.
    • Vaccinations: Routine and influenza.

Special Populations

  • Pediatric (beyond infancy): Children with a history of BPD continue to have higher rates of respiratory symptoms (wheezing, cough, exercise intolerance), reduced lung function (obstructive and/or restrictive patterns), and increased risk of asthma and recurrent respiratory infections. Long-term follow-up by pediatric pulmonologists is essential, often involving PFTs, exercise testing, and continued monitoring of growth and development.
  • Geriatric: Not directly applicable as BPD is a pediatric condition. However, adults born prematurely with BPD are now reaching adulthood. There is emerging evidence that they may have an accelerated decline in lung function, increased risk of COPD-like symptoms, bronchiectasis, and right ventricular dysfunction in later life.
  • Pregnancy: Not applicable.
  • Comorbidities:
    • Congenital Heart Disease (CHD): BPD is common in infants with complex CHD, especially those with increased pulmonary blood flow (e.g., large VSD). Management requires close collaboration between pulmonology and cardiology to optimize hemodynamics and respiratory status.
    • Neurological Impairment: High comorbidity with cerebral palsy, developmental delay, and other neurological sequelae of prematurity. This impacts feeding, cough reflex, and overall care complexity.
    • Airway Malformations: Tracheomalacia, bronchomalacia, subglottic stenosis can coexist and complicate BPD management, often requiring bronchoscopy for diagnosis and potentially surgical intervention (e.g., tracheopexy).
    • Pulmonary Hypertension: Its management is critical and often takes precedence in severe BPD, with specific therapies used to reduce afterload and improve RV function.

Clinical Pearls

  • Diagnostic:
    • Don't underestimate "new BPD": CXR may look surprisingly clear, but the child needs significant support. Rely on the clinical definition (oxygen requirement at 36 weeks PMA).
    • Pulmonary Hypertension (PH) is critical: Always screen for PH with an echocardiogram in moderate-to-severe BPD. It significantly impacts prognosis.
    • Growth is a vital sign of lung health: Poor weight gain often signals inadequate caloric intake OR increased work of breathing. Address both vigorously.
  • Treatment:
    • Oxygen is a drug: Titrate carefully to target SpO2 90-95%. Avoid both hypoxemia and hyperoxia. Hypoxia is detrimental for PH and neurodevelopment; hyperoxia contributes to lung damage.
    • Fluid management is key: Avoid overhydration, which exacerbates pulmonary edema, but ensure adequate hydration for airway secretions. Diuretics are often necessary.
    • Think beyond the lungs: BPD is a systemic disease. Address nutrition, neurodevelopment, and cardiac comorbidities.
    • Prevention is paramount: Antenatal steroids, gentle ventilation, and caffeine are evidence-based prevention strategies.
  • Pitfalls:
    • Over-reliance on chest X-ray: CXR changes may not correlate with clinical severity in "new BPD".
    • Ignoring pulmonary hypertension: Untreated PH can lead to cor pulmonale and death.
    • Aggressive weaning of oxygen: Can lead to desaturations, increased work of breathing, pulmonary vasoconstriction, and growth failure. Wean slowly and safely.
    • Unnecessary prolonged systemic steroid use: Known long-term neurodevelopmental and growth side effects.
    • Failure to provide adequate nutrition: Underfeeding exacerbates growth failure and impairs lung repair.
    • Underestimating neurodevelopmental risk: Early referral for developmental follow-up is crucial.

Recent Updates

  • Guidelines:
    • American Academy of Pediatrics (AAP) Clinical Report (2014): "Bronchopulmonary Dysplasia" provides a comprehensive overview of diagnosis, prevention, and management, emphasizing the NIH 2001 definition.
    • European Academy of Paediatric Societies (EAPS) Guidelines: Often align with AAP, with nuances for practice in their regions.
    • Recent consensus statements continue to emphasize personalized care, gentle ventilation, and early detection/management of pulmonary hypertension.
  • Evidence:
    • Targeted oxygen saturation: Continued research supports a moderate saturation target (e.g., 90-95%) rather than higher targets, to balance between preventing hypoxemia and avoiding hyperoxia.
    • Non-invasive ventilation: Growing evidence supports early and sustained use of non-invasive respiratory support (CPAP, NIPPV, HFNC) to reduce the need for invasive ventilation and BPD incidence.
    • Pulmonary Hypertension: Increased recognition of its prevalence and prognostic significance, leading to earlier screening and aggressive management with specific vasodilators.
    • Long-term outcomes: Longitudinal studies continue to track neurodevelopmental, lung function, and cardiovascular outcomes into adulthood for BPD survivors.
  • Controversies:
    • Optimal timing and duration of systemic corticosteroids: While short courses may aid extubation, concerns about long-term neurodevelopmental impairment persist. Inhaled corticosteroids have shown limited benefit in preventing BPD.
    • Role of Vitamin A supplementation: While some studies show modest benefits in reducing BPD, its use is not widespread due to practical challenges and inconsistent results across populations.
    • Optimal management of PDA: Whether to aggressively treat all PDAs or only hemodynamically significant ones remains debated due to potential adverse effects of medical/surgical closure.
    • Long-term impact of new BPD on adult lung health: As the first cohorts of "new BPD" survivors reach adulthood, the full spectrum of long-term sequelae is still being elucidated.

Key References

  • Guidelines:
    • Jobe AH. The new bronchopulmonary dysplasia. Curr Opin Pediatr. 1999;11(2):145-148. (Introduced the concept of "new BPD")
    • Northway WH Jr, Rosan RP, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276(7):357-368. (Original description of BPD)
    • Bancalari E, et al. Bronchopulmonary Dysplasia: New Insights for the Pediatrician. Pediatrics. 2014;133(4):e1122-e1136. (AAP Clinical Report)
  • Studies:
    • Schmidt B, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357(19):1893-1902. (CAP trial, demonstrating benefits of caffeine)
    • Laughon M, et al. Bronchopulmonary Dysplasia: Predictors and Pitfalls. Neonatology. 2009;95(4):307-313.
    • Sosenko I, et al. Pulmonary hypertension and BPD. Pediatric Res. 2013;74 Suppl 1:S13-22.
  • Reviews:
    • Abman SH. Bronchopulmonary Dysplasia: "a New-Born" Again Disorder. Pediatr Res. 2009;65(5):502-506.
    • Walsh MC, et al. The diagnosis and assessment of bronchopulmonary dysplasia. Semin Perinatol. 2007;31(1):15-22.
    • Kinsella JP, et al. The Pulmonary Vasculature in Bronchopulmonary Dysplasia. Semin Perinatol. 2017;41(7):423-432.

Disclaimer: This information is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read here. Clinical judgment must always be exercised.

Dr. Vivek's AI | For Educational Purposes Only